key: cord-1055961-lwok13m5
authors: Grant, Jennifer; Özkan, Alican; Oh, Crystal; Mahajan, Gautam; Prantil-Baun, Rachelle; Ingber, Donald E.
title: Predicting drug concentrations in PDMS microfluidic organ chips
date: 2021-05-02
journal: bioRxiv
DOI: 10.1101/2021.05.01.442248
sha: 0cde959a4d937736e0d11cf02c4a5b8ef459a78e
doc_id: 1055961
cord_uid: lwok13m5

Microfluidic organ-on-a-chip (Organ Chip) cell culture devices are often fabricated using polydimethylsiloxane (PDMS) because it is biocompatible, transparent, elastomeric, and oxygen permeable; however, hydrophobic small molecules can absorb to PDMS, which makes it challenging to predict drug responses. Here, we describe a combined simulation and experimental approach to predict the spatial and temporal concentration profile of a drug under continuous dosing in a PDMS Organ Chip containing two parallel channels separated by a porous membrane that is lined with cultured cells, without prior knowledge of its log P value. First, a three-dimensional finite element simulation of drug loss into the chip was developed that incorporates absorption, adsorption, convection, and diffusion, which predicts changes in drug levels over time and space as a function of potential PDMS diffusion coefficients and log P values. By then experimentally measuring the diffusivity of the compound in PDMS and determining its partition coefficient through mass spectrometric analysis of the drug concentration in the channel outflow, it is possible to estimate the effective log P range of the compound. The diffusion and partition coefficients were experimentally derived for the antimalarial drug and potential SARS-CoV-2 therapeutic, amodiaquine, and incorporated into the model to quantitatively predict the drug-specific concentration profile over time measured in human Lung Airway Chips lined with bronchial epithelium interfaced with pulmonary microvascular endothelium. The same strategy can be applied to any device geometry, surface treatment, or in vitro microfluidic model to predict the spatial and temporal gradient of a drug in 3D without prior knowledge of the partition coefficient or the rate of diffusion in PDMS. Thus, this approach may expand the use of PDMS Organ Chip devices for various forms of drug testing.

Organs-on-chips (Organ Chips) are microfluidic culture devices lined by living human cells that reconstitute human organ-level structures as well as physiology and pathophysiology. Their ability to model many features of a functional human organ, such as the response to viral infection, 1,2 bacterial infection, 3, 4 disease states, [5] [6] [7] [8] [9] and clinically relevant drug exposure pharmacokinetic (PK) profiles, 10 make Organ Chips particularly useful for drug development and toxicity studies. Organ Chips are often fabricated out of poly-dimethylsiloxane (PDMS) because it is an oxygen permeable, transparent, biocompatible, and elastomeric polymer. 3, 11 However, PDMS can strongly adsorb some hydrophobic small molecules from solution as well as accumulate these molecules into its bulk volume. Together, adsorption and absorption can decrease the effective dosing concentration, making it difficult to predict actual drug concentrations experienced by the cells. Thus, development of a method to overcome this limitation could benefit the entire Organ Chip field.

The logarithm of the octanol-water partition coefficient (log P) is frequently used to approximate the extent of PDMS absorption, where compounds with high log P have a greater tendency to bind to or be absorbed by PDMS. Partition coefficients have been experimentally determined using analytical techniques such as fluorescence, 12 UV-vis, 13 or IR spectroscopy, 13 and computationally predicted with quantitative structure-activity relationship (QSAR) 14, 15 or molecular dynamics (MD) 16 models. However, the partition coefficient alone cannot predict the extent of binding, and past work suggests that it should be combined with the topological polar surface area (TPSA) 12, 17 or the number of H-bond donors 13 to improve the accuracy of bioavailability predictions in PDMS-based microfluidic devices. Although physiochemical descriptors are useful for describing the extent of compound loss into PDMS devices, they cannot be used to quantitatively predict drug loss because it is a dynamic process that depends strongly on a variety of factors including absorption, convection, diffusion, medium composition, dosing time, cell type, and surface treatment, in addition to adsorption.

A more comprehensive understanding of drug loss can be obtained by combining computational models and experimental data acquired directly from the PDMS Organ Chip devices used for in vitro culture. A one-dimensional (1D) simulation model has been developed that predicts drug loss in a PDMS device by combining computational fluid dynamics (CFD) with drug-PDMS binding kinetics, which suggested that drug loss can be minimized by increasing the flow rate, decreasing channel height, or decreasing channel width. 13 This approach demonstrated the potential to estimate the concentration of the drug in a simple single-channel microfluidic culture device by combining experimentally derived constants with computational simulations of physical processes. However, it does not provide a way to predict how drug concentrations vary over time and space within microfluidic Organ Chip devices that contain two parallel channels separated by a membrane lined by living cells, which have been shown to faithfully recapitulate the physiology and pathophysiology of many different human organs. 10, 18 Two-channel microfluidic Organ Chips can faithfully recapitulate dynamic pharmacokinetic (PK) profiles that are observed in vivo because the drug is perfused through endothelium-lined vascular channels and physiologically relevant tissue-tissue interactions permit analysis of clinically relevant drug fluxes between compartments. We have previously shown that PK parameters can be estimated in a vascularized human bone marrow-on-a-chip (BM chip) by fitting a three-compartment PK model to LC-MS/MS-quantified drug concentrations from the chip outflows. 19 It is possible to increase the accuracy of the PK model and in vivo extrapolations by accounting for drug loss due to PDMS absorption. A PK model of a Human-Body-on-Chips system incorporated drug loss due to PDMS absorption by performing mass spectrometric analysis of the drug concentration in the outflows of blank chips and incorporating the fractional loss into the model. 10 Although this model quantitatively predicted PK parameters for orally and intravenously administered drugs, it cannot be used to accurately predict the spatial and temporal concentration of the drug inside the chip throughout the dosing period because the model did not consider diffusion of the drug into bulk PDMS and it simplified the geometry of the Organ Chip into two-dimensional (2D) domains. Additionally, the loss due to PDMS absorption was performed by mass spectrometric analysis of blank chips without cultured cells, which can bias the extent of absorption. Thus, there is a clear need for a more comprehensive model that simulates three-dimensional (3D) drug concentrations in chips lined with cultured cells and incorporates all physical processes that contribute to drug loss. This is necessary to quantitatively predict drug concentrations inside the chip throughout an exposure period and thereby guide dosing strategies, evaluate toxicities, and analyze pharmacokinetic properties.

Here, we describe a combined experimental and computational approach that predicts spatial and temporal drug concentration profiles in 3D under continuous dosing in two-channel, microfluidic, Organ Chips lined with cultured living cells. This strategy involves the development of a finite element simulation of drug absorption in a PDMS Organ Chip as well as experimental quantification of the diffusion and partition coefficients of the drug. The computational model is then used to predict drug concentrations that the cells experience at any time within the microfluidic channels of the chip. We applied this method towards predicting levels of the antimalarial drug amodiaquine when administered continuously under flow in human Lung Airway Chips, which recently resulted in identification of this drug as a potential SARS-CoV-2 therapeutic. 1 This strategy can predict compound loss due to PDMS absorption in any device composition, and thus, it should help to improve experimental design and analysis of doseresponse efficacy and toxicity studies in PDMS Organ Chips.

The mass transport of a drug in a microfluidic Organ Chip is controlled by diffusion, convection, dissolution, dose, device geometry, temperature, and pressure. 20 We carried out 3D simulations that incorporate each of these factors to understand the drug distribution in the microfluidic channels. The Organ Chip we model is a commercially available PDMS microfluidic culture device that contains two parallel fluidic channels separated by a porous PDMS membrane, which is lined by living epithelium on one side and endothelium on the other (Fig.   1a) . A SOLIDWORKS rendering of the PDMS Organ Chip was imported into COMSOL Multiphysics software and fluidic domains were assigned to the apical and basal channels (Fig   1b) . The height of the epithelium and endothelium (3.9 µm and 1 µm, respectively) was experimentally determined from microscopic cross-sections of human Lung Large Airway Chips lined by primary human bronchial epithelium interfaced with primary human pulmonary microvascular endothelium and incorporated into the total height of the central membrane; the membrane pores that represent 3% of the total membrane area were removed to increase computational efficiency. We used the human Lung Airway Chip as a starting point to develop this modeling approach because we had found that the antimalarial drug, amodiaquine, significantly inhibits infection of the epithelium by a pseudotyped SARS-CoV-2 virus when flowed through the vascular channel of the device at a clinically relevant dose of 1.24 µM (the maximum concentration or Cmax of amodiaquine in human blood), and its ability to inhibit infections by native SARS-CoV-2 was confirmed in vitro and in animal studies. 1 Amodiaquine is known to participate in hydrophobic interactions with lipids and proteins, 21, 22 and thus, there was a good chance that it might adsorb to the walls of PDMS channels. So, we wanted to determine the effective drug concentration that the cells were exposed to in this microfluidic chip under the experimental conditions we utilized; however, we did not know the log P for this drug in the Organ Chip environment with cultured cells and extracellular matrix. Thus, to fully characterize the concentration of amodiaquine in the Lung Airway Chip, we set out to develop a combined experimental and computational approach that predicts the concentration of the drug in the chip over time.

A drug must first adsorb to the channel wall before it enters into the bulk PDMS.

Dissolution of a drug from the cell culture medium onto the PDMS wall is described using the partition coefficient (P):

where is the concentration of drug in PDMS and is the concentration of drug in cell culture medium. The partition coefficient was implemented for all medium-PDMS interfaces in the Organ Chip geometry. After adsorption onto the wall surface, the drug diffuses into the bulk polymer down a concentration gradient at a rate described by Fick's second law of diffusion. In show that absorption to the channel wall generates a concentration gradient that radially extends outwards from the center of the basal channel with lower concentrations along its lateral sidewalls (Fig. 2b) . The concentration gradient in the basal channel is anisotropic because the 90° corners generate a non-uniform velocity distribution (Fig. S1 ). These models reveal that the drug with P= 400 takes more time to saturate the basal channel because it rapidly absorbs into the channel walls. At both simulated P values, drug enters the membrane from the basal channel and begins to diffuse into the apical channel medium ( Fig. 2b and Fig.   S2 ). 2D heat maps through the center of the basal channel along the xy plane show that a concentration gradient also exists along the fluidic stream because adsorption depletes the drug from the medium and lowers the downstream concentration along the length of the channel ( Fig. 2c) . Together, these data emphasize that drug absorption and adsorption are spatially and temporally dependent processes and both influence the concentration of drug dose exposure experienced in this in vitro chip model. Thus, applying a single constant to describe drug loss in an Organ Chip will not capture these dynamic concentration distributions and may inaccurately describe the dosing window. (Fig. 3a) . Conversely, more drug loss is observed for compounds with high PDMS diffusivity (Dpdms > 1 x 10 -13 m 2 /s) because the compound travels down its concentration gradient faster and does not accumulate near the wall.

We also varied P from 25-600 while keeping Dpdms constant at 1 x 10 -13 m 2 /s and observed that drugs with higher P values (P>200 = log P>2.3) show significant depletion in the basal channel ( Fig. 3b) . As expected, drugs with high partition coefficients adsorb more rapidly to the channel walls and deplete from the medium at a higher rate. The simulations emphasize that in vitro models with the same flow rate and dosing concentration can experience dramatically different compound loss depending on the value of P and Dpdms. Our work complements past studies which concluded that drug loss in PDMS can be significant for log P > 2.7, but total loss also depends on diffusivity, convection, and dosing time. 26 Therefore, drug loss should be simulated and evaluated under the same conditions as used in the in vitro model of interest. 

Using amodiaquine to test the approach, the diffusivity of the drug was determined by correlating Fick's second law to the fluorescence distribution of a surrogate compound inside an Organ Chip. The diffusivity of a compound in a solid polymer is inversely proportional to the molecular size. 26, 27 Fluorescein isothiocyanate (FITC) was selected as a surrogate compound to amodiaquine because it is similar in molecular weight, structure, and hydrophobicity (Table S1) ,

and FITC absorption into the bulk PDMS of the Organ Chip can be quantitatively and spatially analyzed using fluorescence microscopy. We flowed FITC into the Organ Chip at 1.24 µM, the Cmax of amodiaquine, and observed entry into the bulk polymer through the PDMS wall (Fig.   4a ). The diffusion coefficient was obtained by fitting the analytical solution of Fick's second law to the experimental data by varying the value of Dpdms and minimizing the sum of squares (Fig.   4b) . 26 

With knowledge of the approximate Dpdms value, we estimated P by continuously (Fig. 6a, Fig. S3 ). Heat maps of the amodiaquine concentration profile inside the basal channel at earlier time points show a significant depletion zone near the channel walls (Fig. 6b, c) . The drug becomes more uniformly distributed across the channel over time because the drug approaches a saturation limit near the PDMS wall.

These results reveal that use a pretreatment step would allow the drug concentration to reach near-saturation before introducing a perturbation (e.g. viral or bacterial infection) and that dosing the drug at a higher concentration could compensate for the loss due to adsorption and absorption, and hence allow the in vitro model to more accurately approach the clinical Cmax. 

The combined experimental-computational strategy described here provides a way to quantitatively predict the spatial and temporal gradient of a drug in 3D within a two-channel PDMS Organ Chip without prior knowledge of the partition coefficient or the rate of diffusion in PDMS. Importantly, this approach addresses a longstanding limitation associated with the use of microfluidic culture devices, which are frequently composed of PDMS, to more accurately inform dosing studies and define toxicity thresholds. We simulated drug loss in 3D and show that it is a spatially and temporally dynamic process that depends on the physicochemical properties of the drug and the experimental Organ Chip model. By experimentally measuring the diffusion coefficient of the compound into PDMS and determining its partition coefficient by measuring its levels in the channel outflow using mass spectrometry, we are able to determine the effective log P range of the compound. We applied this strategy to predict the concentration of amodiaquine in a human Lung Airway Chip after 72 h of continuous dosing and show that the concentration reduces by 13-34% in the center of the basal channel, which affects analysis of prior results and design of future studies with this drug.

Previous work has shown that PDMS can strongly bias drug dosing studies and influence cell behavior. For example, when tested using a multiple myeloma cell line, the IC50 for two cancer drugs (bortezomib and carfilzomib) was shown to be 4.3-fold greater in a microfluidic device composed of PDMS compared to polystyrene and cyclo-olefin polymer. 30 Similarly, human embryonic kidney (HEK) cells responded to fluoxetine (Prozac) treatment when cultured in polystyrene, but not PDMS microchannels. 31 To demonstrate the effect of PDMS on cell behavior, one study observed a reduction in CD38 expression on human umbilical cord bloodderived CD34 + cells cultured on PDMS due to the loss of all-trans retinoic acid into the PDMS. 32 Therefore, understanding and quantifying drug loss in PDMS microfluidic culture systems is critical because it can shift dose-response curves, bias toxicity thresholds, and alter cell behavior.

In a previous study, the loss of drug due to PDMS absorption was incorporated into a PK model of multiple fluidically linked Organ Chips by experimentally measuring the drug in the channel outflows of blank chips and calculating the fractional loss. 10 It is important to note that another potential limitation of our approach is that the PDMS membrane, epithelium, and endothelium are modeled as a homogenous PDMS block, and we assume that drug passively diffuses through the block at a rate described by Fick's second law.

The accuracy of the predicted range of log P values may be improved in the future by measuring accumulation of the drug in the cells and apparent drug permeability (Papp), and incorporating this information into the model. The concentration of drug in the basal channel outflow can then be combined with the simulation of drug loss and fit to a PK model to estimate the rate and extent of distribution. 19 Furthermore, Papp can be determined by flowing a tracer molecule into the basal channel and calculating the fraction of molecule that entered the apical channel. 1, 10, 39 Organ Chips and other microfluidic culture models are commonly fabricated with PDMS, but compound loss can bias results and affect cell behavior. In this study, we described a 

A 

where is ∇ the gradient operator and ∇ 2 is the square of vector Laplacian, P is pressure, u is velocity, μ is viscosity, and is the density of medium. Apical and basal inlet flow rates were set as 0 µL/h and 60 µL/h, respectively, for the flow simulations. The outlet boundary condition was set to zero gauge pressure and a no-slip boundary condition was set at the channel walls.

Fick's second law was applied to model drug transport in culture medium (Equation #4) and PDMS (Equation #5):

where is the diffusivity of drug in cell culture medium, is the diffusivity of drug in PDMS, is the concentration of drug in medium, is the concentration of drug in PDMS, and is the density of PDMS.

The partition coefficient was implemented in COMSOL by applying the following pointwise constraint expression at all PDMS-medium and PDMS-cell interfaces: Table S2 .

This protocol is based on the methods described in Si supplemented with 1% penicillin-streptomycin, 10 ng/mL of VEGF and 1 μg/mL ascorbic acid.

The apical channel of the chips were flushed for 2 minutes at 1000 μL/h. After flushing, the flow rate in the apical channel was set to 0 µL/h and the Zoë was programmed to "Air". Medium flowed through the basal channel at 30 μL/h. The apical surface of the epithelium was rinsed once weekly with PBS (-/-) to remove cellular debris and mucus. Drug was dosed into human Lung Airway Chips after 12 days of ALI culture. 

where , is the concentration of the drug on the PDMS side of the medium-PDMS interface, x is the distance away from the wall into bulk PDMS, is the diffusion coefficient of the drug in PDMS, t is the elapsed time, and ( , ) is the concentration of the compound. ( , ) was fit to the experimentally determined concentration profile by varying Dpdms and minimizing the sum of squared residuals. 26, 28 The diffusion coefficient was calculated from n=3 experimental replicates and R 2 > 0.98 for each replicate.

Amodiaquine dihydrochloride dihydrate (cat. #A2799; Sigma-Aldrich) was dissolved in 

The concentration of amodiaquine in the basal outflow was computationally simulated using the experimentally determined Dpdms (Dpdms = 3.8 ± 4.5 x 10 -13 2 ). A boundary probe was placed on the basal outlet and programmed to output the average drug concentration. We first performed a course estimate of the P value range that fit the LC-MS/MS data. We 

All experimental results are expressed as means ± standard deviation (SD). Each experiment was conducted with a sample size of n=3 chips per condition. 

D.E.I. holds equity in Emulate Inc. and is a member of its board of directors and chairs its scientific advisory board.

Drug Targeting and Stimuli Sensitive Drug Delivery Systems

Drugbank: a comprehensive resource for in silico drug discovery and exploration